Retrieved from SingleCare-e
Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial
That can make your hair feel more fragile and look less full
Dosage: KwikPen Tirzepatide 2.5mg is administered once weekly via subcutaneous injection The 2.5mg dose is typically used as the starting stage before gradual dose escalation Can be induced in the abdomen, thigh, or upper arm Use on the same day each week, at any time, with or without food Side Effects: Nausea or vomiting Diarrhea or constipation Low appetite Abdominal pain Mild injection-site reactions Precautions: Monitor the kidneys and liver functioning while and during treatment Not advised for type 1 diabetes or patients with diabetic ketoacidosis Avoid use in pregnancy or breastfeeding without medical direction Report severe gastrointestinal symptoms immediately Medical supervision essential for patients transitioning from insulin or other GLP-1 agents Contraindications: Thyroid history of Personal or family Multiple endocrine neoplasia syndrome type 2 Severe gastrointestinal disorders Known hypersensitivity to Tirzepatide Severe dehydration or vomiting Interactions: May affect absorption of oral medications due to delayed gastric emptying Combined use with insulin or sulfonylureas may increase hypoglycemia risk Avoid combination with other GLP-1 agonists Caution with diuretics or medications affecting fluid balance
But my weight was keeping me from doing things I really loved (and I didn't love looking in the mirror), and I'm happy I have my active, energetic self back
At ShillMed, we use Semaglutide as part of a broader strategy, never as a standalone solution
